Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C

J Antimicrob Chemother. 2021 Jun 18;76(7):1947-1948. doi: 10.1093/jac/dkab076.

Authors

Takumi Umemura^{1

2}, Kazuki Nishikawa³, Yoshikazu Mutoh^{2

4}, Hajime Sasano⁵, Koji Kozaki¹, Tetsuya Yamada¹, Toshihiko Ichihara²

Affiliations

¹ Department of Pharmacy, Tosei General Hospital, Seto, Aichi, Japan.
² Department of Infection and Prevention, Tosei General Hospital, Seto, Aichi, Japan.
³ Department of Gastroenterology, Tosei General Hospital, Seto, Aichi, Japan.
⁴ Department of Infectious Disease, Tosei General Hospital, Seto, Aichi, Japan.
⁵ Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.

No abstract available

Publication types

Case Reports

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents* / therapeutic use
COVID-19 Drug Treatment*
Humans
Liver Cirrhosis* / complications

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine